Stocks climbing to 10 times their original price are rare breeds -- but they're not impossible to find. Especially when you have Fools for friends.
The market's best stocks include companies that have risen dozens of times in value by taking advantage of the market's weaknesses. These aren't penny stocks; they're viable companies with sound business prospects that are achieving phenomenal returns. Finding just one or two of these monstrously successful firms can help you establish a winning portfolio.
Stalking the monster
To find tomorrow's winners, we've enlisted the help of the more than 170,000 monster trackers at Motley Fool CAPS. We've compiled a list of the most successful CAPS members, dubbed All-Stars, whose picks have doubled, tripled, or even quadrupled in price. Then we've plucked out some of their recent picks for stocks they find equally promising.
Recent Stock Pick
Score is how many percentage points that pick is beating the S&P 500.
Of course, this is not a list of stocks to buy -- or, for those monster stocks that our CAPS All-Stars have already found, sell. Just consider them starting points for your own further research of extreme buying opportunities.
In search of Bigfoot
Although flying under the radar of Wall Street, the CAPS community is tuning in to medical instruments maker Harvard Bioscience, with 95% of the members rating the company believing it will outperform the broad indexes.
In giving the stock a thumbs-up, JakilaTheHun pointed to its management team and its ability to create shareholder value:
Very well-run company, with great management, and an excellent track record of success. ROI is at 18% and ROE is at 23%, according to Finviz. Not "cheap" per se, but about fairly valued right now. I can't claim to know much about this industry, but my green thumb for this one is a bet of management continuing to earn above-market returns on their investments.
Last quarter, profits fell 42% to $2.2 million, but the year-ago period was assisted by a one-time gain. Although its end-use customers typically hail from universities and government labs, Amgen, AstraZeneca, and Johnson & Johnson
Head over to the Harvard Bioscience CAPS page and pahk your thoughts in the medical device maker's yahd.
Cheap by any measure
With shares trading at less than half their 52-week highs, investors are hoping for much out of Trident Microsystems. The integrated circuit maker has been suffering from the reticence of consumers to part ways with their money for pricey consumer electronics. While next quarter's earnings might not be stunning, the long-term prospects for growth make this a good time to consider the stock.
According to the market researchers at Strategy Analytics, as tough a sell as 3-D TVs were this past Christmas, more than a third of U.S. households will own one by 2014. It's estimated 900 million sets will be installed globally. That's a lot of chips they're going to need. Of course, look for Sony and Samsung to prosper from the sale of sets, but Trident and Broadcom
CAPS member HollowMountain likes that it runs a fairly lean, agile operation: "Growing faster than competitors with no debt and it does business in a part of the world that has exhibited explosive growth. Plus over $100M cash to work with."
You can see how much 3-D chips into the growth equation for Trident by adding it to the Fool's free portfolio tracker.
A bright idea
Despite another disappointing earnings report, Marvell Technology is a company Wall Street and Main Street should actually like. It's proving quite adept at generating profits, making its stock look very cheap. That's not so easy to find in the technology sector, but if it can make inroads into mobile radio chips that have served Spreadtrum Communications
Over 94% of the almost 1,400 CAPS members rating Marvell believe it will beat the Street going forward. TigerAnalyst thinks it's got the wherewithal to get past the current mess: "Strong balance sheet, positive insider activity. Reliant on the consumer, but as the consumer continues to pick up steam should do well."
A chance for scary growth
It takes more than a few All-Star picks and a quick pitch to make buy or sell decisions, so start your own research on these stocks on Motley Fool CAPS and marvel at the range of opinions there.
Johnson & Johnson is a Motley Fool Inside Value selection and a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson and Marvell Technology Group. Motley Fool Alpha LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.